GENE ONLINE|News &
Opinion
Blog

2022-06-10| Licensing

Novartis and Samsung Biologics Sign Low-Profile $81 Million Deal

by Fujie Tham
Share To

Samsung Biologics, the biotechnology division of Samsung Group, is signing a deal worth $81 million with Switzerland-based Novartis. The contract manufacturing (CDMO) giant has not disclosed further details of the deal. 

The regulatory filing also disclosed that the deal amount represents 6.4% of Samsung’s sales in the 2021 fiscal year, which were listed at around $1.2 billion. This news follows Novartis’ latest manufacturing expansion with the approval of its multi-product North Carolina facility.

Related article: Novartis CAR-T Cell Therapy Receives FDA Approval for Third Indication to Treat Follicular Lymphoma

 

Samsung’s Stepping Up Its Drug Manufacturing Efforts

 

In March, Samsung’s biotech arm announced a “multidimensional growth plan” doubling down on three pillars: encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint. 

“As a leading CDMO service provider, we will continue to demonstrate our excellent business operations throughout our value chains to ultimately contribute to saving the lives of patients and build a better future for all,” said John Rim, CEO of Samsung Biologics in its 2022 shareholders meeting.

Samsung Biologics’ latest facility – Plant 4, is expected to be partially operational by October 2022 to support 6 x 10 kilolitre (KL) production capability. The plant is projected to finish construction in mid-2023, six months ahead of schedule. Upon completion, it will be the world’s largest biomanufacturing capacity at a single site.

Samsung Biologics has been expanding gradually over the past few years, and secured manufacturing contracts with GSK, Merck KGaA, Moderna, AstraZeneca, etc.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
M&A
Catalent Scoops Up Fellow CDMO, Metrics, for $475 Million
2022-08-11
Bio Asia 2022: The Future Of CGT In Taiwan
2022-08-08
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!